查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1538255

心臟自主神經調節市場報告：2030 年趨勢、預測與競爭分析

Cardiac Autonomic Control Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

心臟自主神經調節的趨勢與預測

預計到 2030 年，全球心臟自主神經調節市場將達到 229 億美元，2024 年至 2030 年複合年成長率為 7.1%。該市場的主要促進因素是心血管疾病盛行率的上升、人們對心臟健康的認知不斷提高以及人工智慧和基於機器學習的心臟自主調節系統的日益採用。全球心臟自主神經調節市場的未來充滿希望，醫院/診所、家庭使用和研究機構市場都有機會。

心臟自主神經調節：依部位分類

包含按產品類型、應用、最終用途和地區分類的心臟自主調節的全球市場預測。

心臟自主神經調節市場洞察

Lucintel 預測，治療領域將在預測期內經歷最高的成長。

在這個市場中，醫院和診所預計將在預測期內實現最高成長。

在預測期內，北美仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球心臟自主神經調節市場預計將達到 229 億美元。

Q2.市場成長預測是多少：

A2. 2024 年至 2030 年，全球心臟自主神經調節市場預計將以 7.1% 的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要驅動力是心血管疾病盛行率的上升、心臟健康意識的提高以及人工智慧和基於機器學習的心臟自主神經調節系統的日益採用。

Q4.市場的主要細分市場是：

A4. 心臟自主神經調節市場的前景廣闊，在醫院/診所、家庭使用和研究機構市場都有機會。

Q5.市場的主要企業是：

A5. 涉及心臟自主神經調節的主要企業如下：

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計治療藥物將在預測期內達到最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 預計北美在預測期內仍將是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球心臟自主神經調節市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球心臟自主神經調節市場趨勢（2018-2023）與預測（2024-2030）
  • 按產品類型分類的全球心臟自主神經調節市場
    • 心率變異性 (HRV) 監測器
    • 血壓計
    • 心電圖監視器
    • 其他
  • 按應用分類的全球心臟自主調節市場
    • 診斷
    • 治療
    • 研究
  • 按最終用途分類的全球心臟自主神經調節市場
    • 醫院/診所
    • 家庭使用
    • 研究所
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的全球心臟自主神經調節市場
  • 北美心臟自主神經調節市場
  • 歐洲心臟自主神經系統調節市場
  • 亞太心臟自主神經調節市場
  • 其他地區心臟自主神經調節市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
  • 全球心臟自主神經調節市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球心臟自主神經調節市場的產能擴張
    • 全球心臟自主神經調節市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare
簡介目錄

Cardiac Autonomic Control Trends and Forecast

The future of the global cardiac autonomic control market looks promising with opportunities in the hospital and clinic, home use, and research institute markets. The global cardiac autonomic control market is expected to reach an estimated $22.9 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are rising prevalence of cardiovascular diseases, increasing awareness of heart health, and expanding adoption of artificial intelligence and machine learning based cardiac autonomic control system.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cardiac Autonomic Control by Segment

The study includes a forecast for the global cardiac autonomic control by product type, application, end use, and region.

Cardiac Autonomic Control Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Heart Rate Variability (HRV) Monitors
  • Blood Pressure Monitors
  • ECG Monitors
  • Others

Cardiac Autonomic Control Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnostics
  • Therapeutics
  • Research

Cardiac Autonomic Control Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Home Uses
  • Research Institutes
  • Others

Cardiac Autonomic Control Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cardiac Autonomic Control Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cardiac autonomic control companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cardiac autonomic control companies profiled in this report include-

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare

Cardiac Autonomic Control Market Insights

Lucintel forecasts that therapeutic is expected to witness the highest growth over the forecast period.

Within this market, hospital and clinic is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Cardiac Autonomic Control Market

Market Size Estimates: Cardiac autonomic control market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cardiac autonomic control market size by product type, application, end use, and region in terms of value ($B).

Regional Analysis: Cardiac autonomic control market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, applications, end uses, and regions for the cardiac autonomic control market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cardiac autonomic control market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cardiac autonomic control market size?

Answer: The global cardiac autonomic control market is expected to reach an estimated $22.9 billion by 2030.

Q2. What is the growth forecast for cardiac autonomic control market?

Answer: The global cardiac autonomic control market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cardiac autonomic control market?

Answer: The major drivers for this market are rising prevalence of cardiovascular diseases, increasing awareness of heart health, and expanding adoption of artificial intelligence and machine learning based cardiac autonomic control system.

Q4. What are the major segments for cardiac autonomic control market?

Answer: The future of the cardiac autonomic control market looks promising with opportunities in the hospital and clinic, home use, and research institute markets.

Q5. Who are the key cardiac autonomic control market companies?

Answer: Some of the key cardiac autonomic control companies are as follows:

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare

Q6. Which cardiac autonomic control market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic is expected to witness the highest growth over the forecast period.

Q7. In cardiac autonomic control market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cardiac autonomic control market by product type (heart rate variability (HRV) monitors, blood pressure monitors, ECG monitors, and others), application (diagnostics, therapeutics, and research), end use (hospitals and clinics, home users, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cardiac Autonomic Control Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cardiac Autonomic Control Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cardiac Autonomic Control Market by Product Type
    • 3.3.1: Heart Rate Variability (HRV) Monitors
    • 3.3.2: Blood Pressure Monitors
    • 3.3.3: ECG Monitors
    • 3.3.4: Others
  • 3.4: Global Cardiac Autonomic Control Market by Application
    • 3.4.1: Diagnostics
    • 3.4.2: Therapeutics
    • 3.4.3: Research
  • 3.5: Global Cardiac Autonomic Control Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Home Uses
    • 3.5.3: Research Institutes
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cardiac Autonomic Control Market by Region
  • 4.2: North American Cardiac Autonomic Control Market
    • 4.2.1: North American Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.2.2: North American Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others
  • 4.3: European Cardiac Autonomic Control Market
    • 4.3.1: European Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.3.2: European Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others
  • 4.4: APAC Cardiac Autonomic Control Market
    • 4.4.1: APAC Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.4.2: APAC Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others
  • 4.5: ROW Cardiac Autonomic Control Market
    • 4.5.1: ROW Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.5.2: ROW Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cardiac Autonomic Control Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Cardiac Autonomic Control Market by Application
    • 6.1.3: Growth Opportunities for the Global Cardiac Autonomic Control Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cardiac Autonomic Control Market by Region
  • 6.2: Emerging Trends in the Global Cardiac Autonomic Control Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cardiac Autonomic Control Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cardiac Autonomic Control Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Medtronic
  • 7.2: Abbott
  • 7.3: Boston Scientific
  • 7.4: Biotronik
  • 7.5: MicroPort Scientific
  • 7.6: LivaNova
  • 7.7: Nihon Kohden
  • 7.8: Schiller
  • 7.9: Johnson & Johnson
  • 7.10: GE Healthcare